Also known as: Ozurdex, steroids
Dexamethasone is a fluorinated glucocorticoid used broadly for anti-inflammatory and immunosuppressive purposes across rheumatic, allergic, pulmonary, neurologic, oncologic, and endocrine indications. It is available in multiple administration routes including oral, injectable, ophthalmic, and topical forms. It is an established generic essential medicine.
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
The FDA accepted Bristol Myers Squibb’s NDAs for iberdomide and mezigdomide, two CELMoD agents for relapsed/refractory multiple myeloma. Iberdomide has Priority Review and a PDUFA date of Aug. 17, 2026; mezigdomide’s is May 13, 2027. The filings are backed by Phase 3 data, including a 52% PFS risk reduction for mezigdomide.
FDA approved subcutaneous isatuximab-irfc for multiple myeloma. Phase 3 EMN24 trial showed 77% MRD negativity with Isa-KRd quadruplet therapy. Phase 2 study showed 77% hematologic response rate in relapsed/refractory AL amyloidosis.
Cerebral organoids are revealing how Ebola virus persists, aiding treatment research for rare Parkinson's disease, modeling Alzheimer's, and gaining whole-network recording capabilities.
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
The FDA has accepted an NDA for iberdomide in combination with anti-CD38 antibodies for relapsed or refractory multiple myeloma. A phase 2 study reports a 39% near complete response rate for the DaraKPd quadruplet therapy with durable MRD negativity. Preclinical research shows the RXR agonist IRX4204 sensitizes myeloma cells to ferroptosis and enhances lenalidomide efficacy.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
An interim phase 3 analysis showed mezigdomide plus carfilzomib and dexamethasone reduced the risk of progression or death in relapsed/refractory multiple myeloma. The SUCCESSOR-2 study remains ongoing and will assess overall survival and safety.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773220 |
Magnesium Sulphate Versus Dexamethasone With TAP Block for Post-Cesarean Analgesia |
NOT_YET_RECRUITING | NA |
| NCT07770698 |
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07768943 |
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07766421 |
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients |
NOT_YET_RECRUITING | PHASE3 |
| NCT07764978 |
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT |
RECRUITING | PHASE3 |
| NCT07764861 |
A Open-Label Phase in Participants With Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763210 |
Lazarus: IT Therapy for ICANS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07762170 |
Success Rates and Safety of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone Injection Spine Study) |
RECRUITING | PHASE4 |
| NCT07761585 |
Effect of Preoperative Dexamethasone in Preventing Spinal Hypotension In Patients Undergoing Elective Caesarian Section |
COMPLETED | NA |
| NCT07748689 |
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. |
NOT_YET_RECRUITING | PHASE2 |
